Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · IEX Real-Time Price · USD
20.76
+0.74 (3.70%)
At close: Apr 26, 2024, 4:00 PM
20.70
-0.06 (-0.29%)
After-hours: Apr 26, 2024, 7:59 PM EDT

Intellia Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current20232022202120202019201820172016
Market Capitalization
2,0022,7312,7458,7993,214717593694472
Market Cap Growth
--0.54%-68.80%173.78%348.19%20.99%-14.55%46.97%-
Enterprise Value
1,2051,9341,6838,1252,656456279353199
PE Ratio
-5.67-5.67-5.79-32.85-23.94-7.20-6.94-10.27-14.92
PS Ratio
55.1975.2752.67266.2255.4216.6419.4726.5628.64
PB Ratio
1.912.602.228.466.102.662.132.312.25
P/FCF Ratio
-6.69-6.69-7.92-37.01-60.08-6.52-8.78-9.2015.76
P/OCF Ratio
-6.93-6.93-8.24-39.10-64.39-6.95-9.68-10.6313.07
EV/Sales Ratio
33.2253.3132.30245.8145.8010.579.1513.5112.07
EV/EBITDA Ratio
-4.09-4.09-3.61-31.13-20.76-4.85-3.44-5.47-6.51
EV/EBIT Ratio
-4.02-4.02-3.55-30.33-19.79-4.58-3.26-5.22-6.29
EV/FCF Ratio
-4.74-4.74-4.86-34.17-49.65-4.14-4.13-4.686.64
Debt / Equity Ratio
0.110.110.110.070.070.07---
Debt / EBITDA Ratio
-0.24-0.24-0.28-0.28-0.31-0.20---
Debt / FCF Ratio
-0.28-0.28-0.38-0.31-0.73-0.17---
Quick Ratio
8.238.239.455.979.337.987.9311.209.10
Current Ratio
8.668.669.626.119.608.128.0111.329.15
Asset Turnover
0.030.030.040.030.120.130.090.090.07
Return on Equity (ROE)
-43.90%-43.90%-48.70%-33.60%-36.90%-36.60%-30.60%-31.30%-20.30%
Return on Assets (ROA)
-36.40%-36.40%-38.60%-26.70%-27.70%-28.90%-25.00%-23.10%-12.80%
Return on Capital (ROIC)
-44.21%-44.21%-33.53%-24.04%-24.12%-36.90%-32.70%-23.14%-15.33%
Earnings Yield
-24.03%-17.62%-17.27%-3.04%-4.18%-13.88%-14.40%-9.74%-6.70%
FCF Yield
-20.38%-14.94%-12.63%-2.70%-1.66%-15.34%-11.39%-10.87%6.35%
Buyback Yield / Dilution
-15.33%-15.33%-8.57%-26.63%-18.50%-9.70%-19.62%-62.03%-9044.86%
Total Shareholder Return
-15.33%-15.33%-8.57%-26.63%-18.50%-9.70%-19.62%-62.03%-9044.86%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).